Exercise and Pharmacotherapy for Anxiety in Cardiac Patients
Status:
Completed
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
Coronary heart disease (CHD) is the leading cause of death in the United States; more than
600,000 Americans suffer a fatal cardiac event each year. Traditional CHD risk factors such
as high blood pressure, smoking, and elevated cholesterol do not fully account for the timing
and occurrence of CHD events and individuals with elevated levels of anxiety appear to have a
greater risk of cardiovascular events. The present study will examine the impact of aerobic
exercise and Lexapro in the treatment of anxiety and cardiovascular biomarkers among
individuals with CHD.